JP2019194251A5 - - Google Patents

Download PDF

Info

Publication number
JP2019194251A5
JP2019194251A5 JP2019131603A JP2019131603A JP2019194251A5 JP 2019194251 A5 JP2019194251 A5 JP 2019194251A5 JP 2019131603 A JP2019131603 A JP 2019131603A JP 2019131603 A JP2019131603 A JP 2019131603A JP 2019194251 A5 JP2019194251 A5 JP 2019194251A5
Authority
JP
Japan
Prior art keywords
composition
botulinum toxin
subject
toxin component
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019131603A
Other languages
English (en)
Japanese (ja)
Other versions
JP6976997B2 (ja
JP2019194251A (ja
Filing date
Publication date
Priority claimed from JP2018141384A external-priority patent/JP6559849B2/ja
Application filed filed Critical
Publication of JP2019194251A publication Critical patent/JP2019194251A/ja
Publication of JP2019194251A5 publication Critical patent/JP2019194251A5/ja
Priority to JP2021183197A priority Critical patent/JP2022028770A/ja
Application granted granted Critical
Publication of JP6976997B2 publication Critical patent/JP6976997B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019131603A 2008-12-31 2019-07-17 注射用ボツリヌス毒素製剤 Active JP6976997B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021183197A JP2022028770A (ja) 2008-12-31 2021-11-10 注射用ボツリヌス毒素製剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14206308P 2008-12-31 2008-12-31
US61/142,063 2008-12-31
JP2018141384A JP6559849B2 (ja) 2008-12-31 2018-07-27 注射用ボツリヌス毒素製剤

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2018141384A Division JP6559849B2 (ja) 2008-12-31 2018-07-27 注射用ボツリヌス毒素製剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021183197A Division JP2022028770A (ja) 2008-12-31 2021-11-10 注射用ボツリヌス毒素製剤

Publications (3)

Publication Number Publication Date
JP2019194251A JP2019194251A (ja) 2019-11-07
JP2019194251A5 true JP2019194251A5 (https=) 2020-01-16
JP6976997B2 JP6976997B2 (ja) 2021-12-08

Family

ID=42285690

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2011543704A Expired - Fee Related JP5866202B2 (ja) 2008-12-31 2009-12-28 注射用ボツリヌス毒素製剤
JP2015027842A Expired - Fee Related JP6145465B2 (ja) 2008-12-31 2015-02-16 注射用ボツリヌス毒素製剤
JP2017096249A Pending JP2017178954A (ja) 2008-12-31 2017-05-15 注射用ボツリヌス毒素製剤
JP2018141384A Expired - Fee Related JP6559849B2 (ja) 2008-12-31 2018-07-27 注射用ボツリヌス毒素製剤
JP2019131603A Active JP6976997B2 (ja) 2008-12-31 2019-07-17 注射用ボツリヌス毒素製剤
JP2021183197A Pending JP2022028770A (ja) 2008-12-31 2021-11-10 注射用ボツリヌス毒素製剤

Family Applications Before (4)

Application Number Title Priority Date Filing Date
JP2011543704A Expired - Fee Related JP5866202B2 (ja) 2008-12-31 2009-12-28 注射用ボツリヌス毒素製剤
JP2015027842A Expired - Fee Related JP6145465B2 (ja) 2008-12-31 2015-02-16 注射用ボツリヌス毒素製剤
JP2017096249A Pending JP2017178954A (ja) 2008-12-31 2017-05-15 注射用ボツリヌス毒素製剤
JP2018141384A Expired - Fee Related JP6559849B2 (ja) 2008-12-31 2018-07-27 注射用ボツリヌス毒素製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021183197A Pending JP2022028770A (ja) 2008-12-31 2021-11-10 注射用ボツリヌス毒素製剤

Country Status (25)

Country Link
US (5) US9956435B2 (https=)
EP (2) EP2379104B1 (https=)
JP (6) JP5866202B2 (https=)
KR (4) KR102179926B1 (https=)
CN (2) CN102300584A (https=)
AU (6) AU2009332947C1 (https=)
BR (1) BRPI0923731B1 (https=)
CA (1) CA2749757C (https=)
CO (1) CO6400199A2 (https=)
CY (1) CY1120137T1 (https=)
DK (2) DK3332805T3 (https=)
ES (2) ES2908616T3 (https=)
HR (1) HRP20180739T1 (https=)
HU (1) HUE037595T2 (https=)
IL (3) IL213668A (https=)
LT (1) LT2379104T (https=)
MX (1) MX2011007059A (https=)
NO (1) NO2379104T3 (https=)
PL (1) PL2379104T3 (https=)
PT (1) PT2379104T (https=)
RU (1) RU2011125775A (https=)
SG (3) SG10202100698QA (https=)
SI (1) SI2379104T1 (https=)
SM (1) SMT201800215T1 (https=)
WO (1) WO2010078242A1 (https=)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9211248B2 (en) * 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
CA2558676C (en) 2004-03-03 2019-04-16 Essentia Biosystems, Inc. Compositions and methods for topical diagnostic and therapeutic transport
SG160357A1 (en) * 2005-03-03 2010-04-29 Revance Therapeutics Inc Compositions and methods for topical application and transdermal delivery of botulinum toxins
NZ598159A (en) * 2006-12-29 2013-08-30 Revance Therapeutics Inc Transport molecules using reverse sequence hiv-tat polypeptides
CN101842107B (zh) * 2007-07-26 2014-04-23 雷文斯治疗公司 抗微生物肽，组合物和使用方法
US9345836B2 (en) 2007-10-02 2016-05-24 Medimop Medical Projects Ltd. Disengagement resistant telescoping assembly and unidirectional method of assembly for such
US10420880B2 (en) 2007-10-02 2019-09-24 West Pharma. Services IL, Ltd. Key for securing components of a drug delivery system during assembly and/or transport and methods of using same
WO2009044401A2 (en) 2007-10-02 2009-04-09 Yossi Gross External drug pump
US7967795B1 (en) 2010-01-19 2011-06-28 Lamodel Ltd. Cartridge interface assembly with driving plunger
US9656019B2 (en) 2007-10-02 2017-05-23 Medimop Medical Projects Ltd. Apparatuses for securing components of a drug delivery system during transport and methods of using same
PL2271670T3 (pl) 2008-03-14 2015-05-29 Allergan Inc Testy aktywności serotypu A toksyny botulinowej oparte na immunologii
US9393369B2 (en) 2008-09-15 2016-07-19 Medimop Medical Projects Ltd. Stabilized pen injector
US12097357B2 (en) 2008-09-15 2024-09-24 West Pharma. Services IL, Ltd. Stabilized pen injector
AU2009332947C1 (en) 2008-12-31 2019-01-03 Revance Therapeutics, Inc. Injectable botulinum toxin formulations
EP2445521A4 (en) * 2009-06-25 2015-08-26 Revance Therapeutics Inc ALBUMINE-FREE BOTULINUM TOXIN FORMULATIONS
US10071198B2 (en) 2012-11-02 2018-09-11 West Pharma. Servicees IL, Ltd. Adhesive structure for medical device
US10071196B2 (en) 2012-05-15 2018-09-11 West Pharma. Services IL, Ltd. Method for selectively powering a battery-operated drug-delivery device and device therefor
US8157769B2 (en) 2009-09-15 2012-04-17 Medimop Medical Projects Ltd. Cartridge insertion assembly for drug delivery system
PH12012500549A1 (en) * 2009-10-21 2017-08-23 Revance Therapeutics Inc Methods and systems for purifying non-complexed botulinum neurotoxin
US10288611B2 (en) 2009-11-23 2019-05-14 The Johns Hopkins University Lateral flow device for diagnosing microbial infections
US10585098B2 (en) 2009-11-23 2020-03-10 The Johns Hopkins University Optimizing diagnostics for galactofuranose containing antigens
US8348898B2 (en) 2010-01-19 2013-01-08 Medimop Medical Projects Ltd. Automatic needle for drug pump
EP2569031B1 (en) * 2010-05-10 2017-10-11 Medimop Medical Projects Ltd. Low volume accurate injector
KR101134146B1 (ko) * 2010-05-31 2012-04-19 메덱스젠 주식회사 국소 근마비 효과를 갖는 비확산형 보툴리눔 독소와 그의 정제방법
PT2661276T (pt) * 2011-01-07 2017-10-06 Revance Therapeutics Inc Composição tópica que inclui uma tóxina botulínica e um corante
USD702834S1 (en) 2011-03-22 2014-04-15 Medimop Medical Projects Ltd. Cartridge for use in injection device
US9072827B2 (en) 2012-03-26 2015-07-07 Medimop Medical Projects Ltd. Fail safe point protector for needle safety flap
CA2889833A1 (en) * 2012-10-28 2014-05-01 Revance Therapeutics, Inc. Compositions and methods for safe treatment of rhinitis
US9421323B2 (en) 2013-01-03 2016-08-23 Medimop Medical Projects Ltd. Door and doorstop for portable one use drug delivery apparatus
US9011164B2 (en) 2013-04-30 2015-04-21 Medimop Medical Projects Ltd. Clip contact for easy installation of printed circuit board PCB
RU2535115C1 (ru) 2013-05-15 2014-12-10 Бости Трейдинг Лтд Фармацевтический состав, содержащий нейротоксин ботулина
GB201312317D0 (en) * 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
US9480731B2 (en) 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
US10107822B2 (en) 2013-12-16 2018-10-23 The Johns Hopkins University Interferon-gamma release assays for diagnosis of invasive fungal infections
ES2642916T3 (es) * 2014-06-06 2017-11-20 Galit KLEINER-FISMAN Toxina botulínica para su uso en el tratamiento de la paratonia
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
DK3174523T3 (da) * 2014-07-31 2020-09-28 Allergan Inc Formuleringer af biologiske stoffer til intravesikal instillation
JP6643324B2 (ja) * 2014-09-02 2020-02-12 アメリカン シルヴァー リミテッド ライアビリティ カンパニー ボツリヌス毒素及びコロイド状銀粒子
CN107106780B (zh) * 2014-12-23 2020-10-16 莫茨制药有限及两合公司 肉毒杆菌毒素预填充式容器
US10293120B2 (en) 2015-04-10 2019-05-21 West Pharma. Services IL, Ltd. Redundant injection device status indication
PL3284506T3 (pl) 2015-04-13 2021-10-25 Lg Household & Health Care Ltd. Rozpuszczalna mikroigła zawierająca składnik do kontroli uwalniania neuroprzekaźników
KR102099326B1 (ko) * 2015-04-13 2020-04-09 주식회사 엘지생활건강 폴리페놀 전달용 용해성 마이크로니들
US10149943B2 (en) 2015-05-29 2018-12-11 West Pharma. Services IL, Ltd. Linear rotation stabilizer for a telescoping syringe stopper driverdriving assembly
US11207465B2 (en) 2015-06-04 2021-12-28 West Pharma. Services Il. Ltd. Cartridge insertion for drug delivery device
US10576207B2 (en) 2015-10-09 2020-03-03 West Pharma. Services IL, Ltd. Angled syringe patch injector
US9987432B2 (en) 2015-09-22 2018-06-05 West Pharma. Services IL, Ltd. Rotation resistant friction adapter for plunger driver of drug delivery device
JP7044708B2 (ja) 2015-10-09 2022-03-30 ウェスト ファーマ サービシーズ イスラエル リミテッド カスタマイズシリンジの充填方法
AU2016343748A1 (en) * 2015-10-29 2018-05-17 Revance Therapeutics, Inc. Injectable botulinum toxin formulations and methods of use thereof having long duration of therapeutic or cosmetic effect
CN111544704B (zh) 2016-01-21 2022-06-03 西医药服务以色列有限公司 自动注射器中的力牵制
US10646643B2 (en) 2016-01-21 2020-05-12 West Pharma. Services IL, Ltd. Needle insertion and retraction mechanism
CN113041432B (zh) 2016-01-21 2023-04-07 西医药服务以色列有限公司 包括视觉指示物的药剂输送装置
US20170209553A1 (en) * 2016-01-22 2017-07-27 Transderm, Inc. Delivery of botulinum with microneedle arrays
WO2017161076A1 (en) 2016-03-16 2017-09-21 Medimop Medical Projects Ltd. Staged telescopic screw assembly having different visual indicators
JP6957525B2 (ja) 2016-06-02 2021-11-02 ウェスト ファーマ サービシーズ イスラエル リミテッド ３つの位置による針の退避
WO2018026385A1 (en) 2016-08-01 2018-02-08 Medimop Medical Projects Ltd. Partial door closure prevention spring
JP6869327B2 (ja) 2016-08-01 2021-05-12 ウェスト ファーマ サービシーズ イスラエル リミテッド 回転防止カートリッジ
BR112019004935A2 (pt) 2016-09-13 2019-06-04 Allergan, Inc. composições de toxina clostridial não proteíca estabilizada
AU2017360346B2 (en) * 2016-11-21 2023-11-23 Eirion Therapeutics, Inc. Transdermal delivery of large agents
WO2018151832A1 (en) * 2017-02-17 2018-08-23 Allergan, Inc. Microneedle array with active ingredient
JP7604222B2 (ja) * 2017-03-22 2024-12-23 ボンチ インコーポレイテッド 治療用のボツリヌス神経毒素
CN107185042B (zh) * 2017-04-29 2020-09-01 杭州维多利亚医疗美容医院有限公司 一种美容注射剂及其制备方法
MX2019013716A (es) * 2017-05-18 2020-10-12 Revance Therapeutics Inc Métodos de tratamiento para la distonía cervical.
CN113855913A (zh) 2017-05-30 2021-12-31 西部制药服务有限公司(以色列) 用于穿戴式注射器的模块化驱动机构
EP3675900A4 (en) * 2017-08-28 2021-05-05 Revance Therapeutics, Inc. Transmucosal botulinum toxin compositions, kits, and methods for treating bladder disorders
KR20190038292A (ko) * 2017-09-29 2019-04-08 한국프라임제약주식회사 효능 지속시간이 연장된 보툴리눔 독소 조성물
EP3703738A4 (en) * 2017-11-03 2021-09-08 ReVance Therapeutics, Inc. BOTULINIC TOXIN FORMULATIONS AND METHODS OF USE THEREOF IN PLANTARY FASCIITIS, WITH EXTENDED DURATION OF EFFECT
SG11202005239YA (en) * 2017-12-04 2020-07-29 Revance Therapeutics Inc Injectable botulinum toxin formulations and methods of use thereof having high response rate and long effect duration
JP7402799B2 (ja) 2017-12-22 2023-12-21 ウェスト ファーマ サービシーズ イスラエル リミテッド サイズの異なるカートリッジを利用可能な注射器
KR102088104B1 (ko) 2018-06-29 2020-03-11 호서대학교 산학협력단 개망초 꽃 에센셜 오일을 포함하는 신경 근육 관련 질환 예방 및 치료용 조성물
BR112021009554A2 (pt) 2018-12-03 2021-08-17 Eirion Therapeutics, Inc. aplicação melhorada de agentes grandes
CA3139983A1 (en) 2019-05-14 2020-11-19 Eirion Therapeutics, Inc. Delaying peak effect and/or extending duration of response
SG11202111282SA (en) 2020-03-31 2021-11-29 Obi Pharma Inc Clostridium botulinum toxin type a composition, formulation and use thereof
CN115397399B (zh) * 2020-04-08 2025-06-27 玫帝托克斯股份有限公司 一种易于控制排出速度且稳定的肉毒杆菌毒素预填充式注射器剂型
CN120437268A (zh) 2020-06-12 2025-08-08 凯尔格恩有限公司 包含五肽作为活性成分的组合物
KR102940220B1 (ko) * 2021-02-08 2026-03-17 주식회사 대웅 장기 저장이 가능한 보툴리눔 독소 동결건조 제형 조성물
EP4537850A1 (en) 2022-06-10 2025-04-16 Medytox Inc. Composition for stabilizing botulinum neurotoxin, botulinum neurotoxin formulation containing same, and polypeptides for use therein
KR102714765B1 (ko) * 2023-05-04 2024-10-11 주식회사 파마리서치바이오 Dna 단편 혼합물 및 보툴리눔 독소를 포함하는 보툴리눔 독소의 생체 내 지속성이 증가된 지속성 제제
WO2025064729A1 (en) 2023-09-19 2025-03-27 Revance Therapeutics, Inc. Treatment with botulinum toxin in patients in need of a rapid onset cosmetic effect and smoother skin appearance
WO2025229073A1 (en) * 2024-05-01 2025-11-06 Fastox Pharma Sa Aqueous compositions of dantrolene

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
US5877278A (en) 1992-09-24 1999-03-02 Chiron Corporation Synthesis of N-substituted oligomers
DE69329795T2 (de) 1992-10-02 2001-07-05 Genetics Institute, Inc. Zusammensetzung, welche den koagulationsfaktor viii beinhaltet; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator
ES2332905T3 (es) 1993-12-28 2010-02-15 Allergan, Inc. Uso del componente neurotoxico de la toxina botulinica para el tratamiento de trastornos de musculos lisos.
US5512547A (en) 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
US5756468A (en) 1994-10-13 1998-05-26 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
US6444209B1 (en) 1996-10-28 2002-09-03 Wisconsin Alumni Research Foundation Hybrid botulinal neurotoxins
US20030095927A1 (en) 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders
AU2340299A (en) 1998-01-26 1999-08-09 University Of Massachusetts Biologically active hemagglutinin from type a (clostridium botulinum) and methods of use
TW574036B (en) 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
US6358917B1 (en) 1999-08-24 2002-03-19 Jean D. A. Carruthers Cosmetic use of botulinum toxin for treatment of downturned mouth
US6544548B1 (en) 1999-09-13 2003-04-08 Keraplast Technologies, Ltd. Keratin-based powders and hydrogel for pharmaceutical applications
US6844324B1 (en) 1999-11-12 2005-01-18 Massachusetts Institute Of Technology Modular peptide mediated intracellular delivery system and uses therefore
IL149778A0 (en) 1999-11-22 2002-11-10 Universal Preservation Technologies Inc Preservation of sensitive biological material
US20030118598A1 (en) 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
ATE519494T1 (de) 2000-02-08 2011-08-15 Allergan Inc Pharmazeutische zusammensetzungen mit botulinum- toxin
US7780967B2 (en) 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US6670322B2 (en) * 2000-06-01 2003-12-30 Wisconsin Alumni Research Foundation Method of targeting pharmaceuticals to motor neurons
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US20040033241A1 (en) 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
US20030215412A1 (en) * 2000-07-21 2003-11-20 Essentia Biosystems, Inc. Induction of hair growth with vascular endothelial growth factor
US20040220100A1 (en) 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
EP1301213B1 (en) 2000-07-21 2017-01-18 ReVance Therapeutics, Inc. Multi-component biological transport systems
US6787517B1 (en) 2000-12-29 2004-09-07 Allergan, Inc. Agent and methods for treating pain
US20020197278A1 (en) 2001-06-21 2002-12-26 Surromed, Inc. Covalent coupling of botulinum toxin with polyethylene glycol
AU2003211990A1 (en) 2002-02-14 2003-09-04 Chugai Seiyaku Kabushiki Kaisha Antibody-containing solution pharmaceuticals
US7691394B2 (en) * 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
WO2003101483A1 (en) 2002-05-31 2003-12-11 Solux Corporation Pharmaceutical preparation of botulinum neurotoxin, methods of synthesis and methods of clinical use
US20040009180A1 (en) 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
US8119109B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
RU2206337C1 (ru) 2002-10-29 2003-06-20 Общество с ограниченной ответственностью "Токсины и сопутствующие продукты" Лекарственный препарат для лечения мышечных дистоний и способ его получения
US20040086532A1 (en) 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
DE10333317A1 (de) 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
US20060210614A1 (en) * 2003-12-26 2006-09-21 Nastech Pharmaceutical Company Inc. Method of treatment of a metabolic disease using intranasal administration of exendin peptide
US20100266638A1 (en) 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
CN1946431B (zh) * 2004-03-03 2011-12-07 雷文斯治疗公司 用于肉毒毒素的局部施用和透皮递送的组合物和方法
CA2558676C (en) 2004-03-03 2019-04-16 Essentia Biosystems, Inc. Compositions and methods for topical diagnostic and therapeutic transport
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
GB2416122A (en) 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
BRPI0513850A (pt) 2004-07-26 2008-05-20 Merz Pharma Gmbh & Co Kgaa composição terapêutica com uma neurotoxina botulìnica
US20070196364A1 (en) 2004-07-27 2007-08-23 Human Genome Sciences, Inc. Pharmaceutical Formulation and Process
PL1776137T3 (pl) 2004-08-04 2015-03-31 Ipsen Biopharm Ltd Kompozycja farmaceutyczna zawierająca neurotoksynę botulinową
ES2526913T3 (es) 2004-08-04 2015-01-16 Ipsen Biopharm Limited Composición farmacéutica que contiene neurotoxina 2 botulínica
GB2419526A (en) 2004-10-28 2006-05-03 Ipsen Ltd Pharmaceutical composition containing botulinum neurotoxin
US7727537B2 (en) 2005-02-14 2010-06-01 Dpm Therapeutics Corp. Stabilized compositions for topical administration and methods of making same
US7838011B2 (en) 2005-02-14 2010-11-23 Pankaj Modi Stabilized protein compositions for topical administration and methods of making same
CN101160318A (zh) 2005-03-03 2008-04-09 雷文斯治疗公司 用于局部施用和经皮肤递送寡肽的组合物和方法
WO2006096163A1 (en) * 2005-03-03 2006-09-14 Allergan, Inc. Animal product free system and process for purifying a botulinum toxin
SG160357A1 (en) 2005-03-03 2010-04-29 Revance Therapeutics Inc Compositions and methods for topical application and transdermal delivery of botulinum toxins
CN101228187A (zh) * 2005-03-25 2008-07-23 特拉维夫大学拉莫特有限公司 针对突变p53的共同表位的人合成单链抗体及其用途
US8323666B2 (en) 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
US8137677B2 (en) 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
NZ568216A (en) 2005-11-17 2012-09-28 Revance Therapeutics Inc Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
AU2007234612B2 (en) 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
FR2910327B1 (fr) 2006-12-22 2013-04-26 Scras Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida.
JP2010514781A (ja) * 2006-12-29 2010-05-06 ルバンス セラピュティックス インク． Ｈｉｖ−ｔａｔに由来するポリペプチド断片を用いて安定化されるボツリヌス毒素を局所適用及び経皮送達する組成物及び方法
CA2686642A1 (en) 2007-06-01 2008-12-04 Merz Pharma Gmbh & Co. Kgaa Process for providing a temperature - stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin
CN101842107B (zh) 2007-07-26 2014-04-23 雷文斯治疗公司 抗微生物肽，组合物和使用方法
WO2009056651A1 (en) 2007-11-02 2009-05-07 Cytos Biotechnology Ag Angiotensin-carrier formulation
US9107815B2 (en) 2008-02-22 2015-08-18 Allergan, Inc. Sustained release poloxamer containing pharmaceutical compositions
KR20090120222A (ko) 2008-05-19 2009-11-24 (주)메디톡스 식물 유래 성분 함유 배지 및 가요성 폐쇄 용기를 이용하여클로스트리디움 보툴리눔 독소를 생산하는 방법
WO2010056922A2 (en) * 2008-11-12 2010-05-20 Kythera Biopharmaceuticals, Inc. Systems and methods for delivery of biologically active agents
KR20110106346A (ko) 2008-12-10 2011-09-28 알러간, 인코포레이티드 클로스트리디움 독소 약제학적 조성물
AU2009332947C1 (en) 2008-12-31 2019-01-03 Revance Therapeutics, Inc. Injectable botulinum toxin formulations
EP2248518B1 (en) 2009-04-17 2013-01-16 Merz Pharma GmbH & Co. KGaA Formulation for stabilizing proteins, peptides or mixtures thereof.
EP2445521A4 (en) 2009-06-25 2015-08-26 Revance Therapeutics Inc ALBUMINE-FREE BOTULINUM TOXIN FORMULATIONS
PH12012500549A1 (en) 2009-10-21 2017-08-23 Revance Therapeutics Inc Methods and systems for purifying non-complexed botulinum neurotoxin
SG181420A1 (en) 2009-10-30 2012-07-30 Revance Therapeutics Inc Device and method for topical application of therapeutics or cosmetic compositions
JP5990176B2 (ja) 2010-10-12 2016-09-07 メルツ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト アウフ アクティーン タンパク質の安定化に好適な哺乳動物性賦形剤非含有製剤
PT2661276T (pt) 2011-01-07 2017-10-06 Revance Therapeutics Inc Composição tópica que inclui uma tóxina botulínica e um corante
WO2012134240A2 (ko) 2011-03-31 2012-10-04 (주)메디톡스 보툴리눔 독소의 동결건조제제
US20130224268A1 (en) 2012-02-27 2013-08-29 Newgen Biopharma Corp. Topical delivery of hormonal and non hormonal nano formulations, methods of making and using the same
CN107106780B (zh) 2014-12-23 2020-10-16 莫茨制药有限及两合公司 肉毒杆菌毒素预填充式容器
HUE052023T2 (hu) 2016-05-27 2021-04-28 Ipsen Biopharm Ltd Triptofánnal vagy tirozinnal stabilizált folyékony neurotoxin készítmény

Similar Documents

Publication Publication Date Title
JP2019194251A5 (https=)
JP2018522563A5 (https=)
FI2970398T3 (fi) Rsv f -prefuusioproteiineja ja niiden käyttö
FI4206216T3 (fi) Adenoassosioituneen viruksen kapsidimuunnoksia ja menetelmiä niiden käyttämiseksi
RU2018114907A (ru) Композиция и способ для лечения заболевания, опосредованного комплементом
JP2011530599A5 (https=)
RU2020121540A (ru) Инъецируемые составы ботулинического токсина и способы их применения с высокими показателями ответа и длительной продолжительностью эффекта
CN101803492A (zh) 原核苯丙氨酸氨裂合酶的组合物及利用其组合物治疗癌症的方法
JP2016506727A5 (https=)
JPH02504279A (ja) インスリン様成長因子１（ｉｇｆ‐１）または因子２（ｉｇｆ‐２）の類縁ペプチド
RU2016146801A (ru) Вакцинная композиция против инфекции, вызванной streptococcus suis
JP2015518818A5 (https=)
FI3227675T3 (fi) Aktiviini-actrii-antagonisteja ja niiden käyttöjä myelodysplastisen oireyhtymän hoitamiseksi
RU2012106150A (ru) Вариантные формы уратоксидазы и их применение
RU2010114018A (ru) Применение пептид тимозина бета 4 индивидуально или в сочетании с цекропином а в качестве терапевтического средства
FI3534939T3 (fi) Rokote sian parvovirusta ja sian hedelmättömyyttä ja respiratorista oireyhtymää aiheuttamaa virusta vastaan ja menetelmän sen valmistamiseksi
JP2017529326A5 (https=)
RU2013126581A (ru) Мутанты стрептокиназы и их ковалентно модифицированные формы
JP2006506942A5 (https=)
JP2015510393A5 (https=)
CN109414426A (zh) 使用精氨酸耗竭剂的组合癌症免疫疗法
RU2016152151A (ru) Препарат, содержащий фактор viii и пептиды фактора фон виллебранда
US7147849B2 (en) Pharmaceutical formulation
RU2012157399A (ru) Пептиды в качестве активных агентов для стабилизации биологических барьеров
RU2017128077A (ru) Составы, содержащие пептиды, ингибирующие мк2